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Abstract: Mutations in the epidermal growth factor receptor (EGFR) are common amongst
those with non-small cell lung cancer and represent a major factor in treatment decisions,
most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that
target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib,
have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is
a favorable option, but almost all patients develop resistance at some time point. There are no
effective treatment options for patients who progress on osimertinib, but ongoing trials will
hopefully address this unmet need. The aim of this review is to provide a comprehensive
review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with
this class of agents.
Keywords: non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase
inhibitor

Introduction
Lung cancer remains the deadliest form of cancer in the United States (US),
accounting for a quarter of cancer mortality and the second most common cancer
diagnosed in 2020.1 Lung cancer mortality has been declining due to efforts of
tobacco use reduction, increased awareness of the health detriments related to
smoking, comprehensive tobacco control programs and screening. While the inci
dence of tobacco-related lung cancer has been declining, there has been an increase
in lung cancer incidence in never or light smokers.2,3
We now know that lung cancer is a heterogeneous disease. In the past, treatment
decisions were primarily dependent on histological classifications such as small cell
and non-small cell lung cancer (NSCLC); and within NSCLC, adenocarcinoma,
squamous cell, large cell neuroendocrine, pleomorphic, large cell neuroendocrine
and undifferentiated carcinoma. While we still incorporate histologic information in
decision-making, treatment algorithms today, particularly for non-squamous
NSCLC, are heavily dependent on molecular profiling of tumors since many of
them harbor driver genetic alterations such as mutations in the epidermal growth
factor receptor (EGFR) and BRAF genes, and rearrangements of the anaplastic
lymphoma kinase (ALK) gene and ROS1 genes that can be targeted with effective
medications.4,5
73

submit your manuscript | www.dovepress.com

Lung Cancer: Targets and Therapy 2020:11 73–103

DovePress

© 2020 Lee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://doi.org/10.2147/LCTT.S258444

Dovepress

Lee et al

The focus of this review is targeting EGFR mutations
in NSCLC with tyrosine kinase inhibitors (TKIs). EGFR is
a member of the ErbB tyrosine kinase receptor family and
is overexpressed in several cancers such as that of lung
and breast.6 Mutations or overexpression of these recep
tors lead to inappropriate activation of the MAPK pathway,
and eventually, uncontrolled cell proliferation. In NSCLC,
EGFR mutations are predominantly seen in adenocarci
noma but are sometimes seen in other subtypes such as
large cell and squamous cell carcinoma.7,8 EGFR has an
extracellular binding domain, trans-membrane segment,
and cytoplasmic tyrosine kinase domain.9 When ligand
binds to the extracellular binding domain, EGFR activates,
dimerizes, and autophosphorylates the tyrosine kinase
domain. This phosphorylation initiates signaling of down
stream pathways involved in cell growth. EGFR mutations
in NSCLC are located on exons 18 through 21, which
encode the ATP binding site of the tyrosine kinase
domain.8 Specifically, 45% have deletion in exon 19% and
40% contain a L858R point mutation in exon 21. Other less
common mutations include exon 19 insertions, p.L861Q, p.
G719X and p.S768I and exon 20 insertions.10,11 Sensitizing
EGFR mutations have been found in up to 50% of Asian
patients and about 10% of Caucasian patients.12 The major
ity of patients with EGFR mutations have never smoked or
were former light smokers. Over the last two decades, small
kinase inhibitors targeting EGFR have made their way into
clinic and transformed the treatment paradigm in subsets of
metastatic lung cancer. In this comprehensive review, we
look to describe current landscape of EGFR TKIs and take
the readers through various generations of these agents.
Table 1 summarizes currently approved EGFR TKIs.13–17
Figure 1 summarizes the timeline of events regarding
EGFR treatment.18–22

First-Generation EGFR TKI
Gefitinib
Gefitinib is a selective, reversible inhibitor of EGFR tyr
osine kinase that binds to the adenosine-triphosphate bind
ing site. Four notable clinical trials were conducted in
Asian patients: IPASS, First-SIGNAL, WJTOG-3405,
and NEJ002.23–26 The Iressa Pan-Asian Study (IPASS)
was a Phase III trial that showed the predictive benefit of
EGFR mutations in metastatic NSCLC. Patients in this
study were untreated East Asian patients with advanced
NSCLC and were either nonsmokers or former light smo
kers. They were randomized 1:1 to receive gefitinib
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250 mg daily or carboplatin and paclitaxel. A total of
1217 patients were randomized with 261 harboring an
EGFR mutation. Approximately half (53.6%) had exon
19 deletions, 111 (42.5%) had a mutation at exon 21
(L858R), 11 (4.2%) had a mutation at exon 20 (T790M),
and 10 (3.8%) had other mutations. The final results
reported improved progression-free survival (PFS) with
gefitinib compared to standard platinum-based doublet
chemotherapy. Notably, the PFS was driven by the
EGFR mutation subgroup, which was significantly longer
in the gefitinib than the chemotherapy group [hazard ratio
(HR)=0.48; 95% CI, 0.36 to 0.64; p<0.001]. PFS was also
shorter in the gefitinib group than in the chemotherapy
group (HR=2.85; 95% CI, 2.05 to 3.98; p<0.001).
Additionally, patients with EGFR mutations had improved
objective response rate (ORR), reduced toxic effects, and
improved quality of life.23
First-SIGNAL, NEJ002, and WJTOG-3405 trials
involving gefitinib further reaffirmed the higher ORRs
and prolonged PFS in patients harboring EGFR mutations
(See Table 2).24–26 These studies established the signifi
cance of the EGFR driver mutation and upfront molecular
testing. Furthermore, the studies that compared gefitinib to
chemotherapy showed no differences in overall survival
(OS) despite prolonged PFS, and this may have been due
to the cross-over effect.46 It was initially approved by the
United States Food and Drug Administration (US FDA) in
2003 as a third-line option for NSCLC after progression
on platinum and taxane chemotherapy irrespective of
mutational status. This drug was then withdrawn from
the market in 2012 and reapproved in 2013 as a first-line
treatment option for patients with a sensitive EGFR
mutation.
Gefitinib has also shown to benefit as adjuvant therapy
for those with completely resected EGFR-mutant stage II–
IIIA NSCLC. Two hundred and twenty-two patients were
randomized to receive either gefitinib or vinorelbine and
cisplatin in a 1:1 fashion in China. Median disease-free
survival (DFS) was significantly longer with gefitinib
compared with vinorelbine and cisplatin: 28.7 months
(95% CI, 24.9 to 32.5) and 18.0 months (95% CI, 13.6
to 22.3), respectively, with a 40% reduction in risk
(HR=0.60, 95% CI, 0.42 to 0.87; p=0.0054). Patients in
the gefitinib group also had less toxicity and improved
quality of life.47 Although gefitinib is not approved for
adjuvant therapy in the US, there is evidence for its use in
this setting.
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250 mg
once
daily

80 mg
once
daily

45 mg
once
daily

Gefitinib15

Osimertinib16

Dacomitinib17

Irreversible EGFR TKI which
targets HER-1, HER-2, and
HER-4 receptors

Irreversible EGFR TKI which
binds to select mutant forms of
EGFR, including T790M, L858R,
and exon 19 deletion at lower
concentrations than wild-type

Reversibly inhibits kinase
activity of wild-type and select
activation mutations of EGFR

Reversibly inhibits overall
HER1/EGFR tyrosine kinase
activity

Covalently binds to EGFR
(ErbB1), HER2 (ErbB2), and
HER4 (ErbB4) to irreversibly
inhibit tyrosine kinase
autophosphorylation and
downregulate ErbB signaling

Mechanism

Take with or without food

Take with or without food

Take with or without food. If
unable, to swallow tablet
whole, place tablet in
120–240 mL water and stir
for 15 minutes and
immediately drink liquid.

Take on empty stomach

Take on empty stomach

Administration

First-line treatment of patients with
metastatic NSCLC with EGFR exon 19
deletion or exon 21 L858R substitution
mutations as detected by an approved test

Treatment of EGFR T790M mutationpositive NSCLC, as detected by an
approved test, in patients who have
progressed on or after EGFR tyrosine
kinase inhibitor therapy

First-line treatment of metastatic NSCLC
in tumors EGFR exon 19 deletions or
exon 21 (L858R) substitution mutations as
detected by an approved test

Treatment of metastatic NSCLC in tumors
with EGFR exon 19 deletions or exon 21
(L858R) substitution mutations as
detected by an approved test either as
first-line, maintenance, or as second or
greater line treatment after progression
following at least 1 prior chemotherapy
regimen

First-line treatment of metastatic NSCLC
in patients whose tumors have
nonresistant EGFR mutations as detected
by an approved test.
Treatment of previously treated metastatic
squamous cell NSCLC that has progressed
following platinum-based chemotherapy.

FDA Approved NSCLC Indication

Avoid
use

N/A

Take
12
hours
before
or
after

Avoid
use

N/A

Take
≥6
hours
before
or 10
hours
after

QTc

Take 6
hours
before
or
after

Take
10
hours
after
and ≥
2
hours
before

N/A

N/A

N/A

N/A

Separate
several
hours

N/A

CYP2D6

CYP3A4,
BCRP, PGP

CYP2D6,
CYP3A4,
BCRP

CYP3A4,
CYP1A2

BCRP,
PGP

CYP2D6

BCRP,
PGP

N/A

N/A

N/A

Inhibitor

N/A

N/A

N/A

N/A

N/A

Inducer

Substrate

Antacids

PPI

H2RA

Metabolism/Transport Effects

Acid Suppressive Therapy
Interactions

Abbreviations: BCRP, breast cancer resistance protein; CYP, cytochrome P450; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; N/A, not applicable; PGP, P-glycoprotein; TKI, tyrosine kinase inhibitors.

150 mg
once
daily

40 mg
once
daily

Dose

Erlotinib14

Afatinib

13

Drug Name

Table 1 Epidermal Growth Factor Receptor Inhibitors
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Figure 1 Epidermal growth factor receptor timeline.

Erlotinib
Erlotinib is a reversible first-generation EGFR TKI that is
FDA-approved for patients harboring EGFR exon 19 dele
tion and exon 21 L858R mutations in the first-line, main
tenance, and second-line settings.14,29-32,48 Prior to 2004,
treatment options for metastatic NSCLC were limited to
chemotherapy irrespective of presence of genetic drivers.
Erlotinib’s approval was based on key trials, which found
improvement in PFS, but not OS when compared to
chemotherapy.4 The OPTIMAL study was a phase III
study performed in EGFR mutated, metastatic NSCLC
Chinese patients who were randomized to erlotinib alone
versus combination carboplatin/gemcitabine chemother
apy. Baseline characteristics were similar amongst the
two groups. The patients in the erlotinib arm had improved
PFS compared to the chemotherapy arm (13.1 vs 4.6
months; HR=0.16, 95% CI, 0.19 to 0.26; p<0.0001) and
the PFS benefit was seen across all subgroups. Patients in
the erlotinib arm also had a lower rate of dose reduction
and treatment discontinuation.30 The EURTAC study was
a randomized trial that compared erlotinib to chemother
apy in non-Asian patients with metastatic NSCLC.
Patients with EGFR exon 19 deletion or exon 21 L858R
mutations and Stage IIIB disease with pleural effusion or
Stage IV disease were enrolled. Participants were
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randomized to daily oral erlotinib or chemotherapy. The
study found improved PFS in the erlotinib arm compared
to chemotherapy (9.7 vs 5.2 months; HR=0.37, 95% CI,
0.25 to 0.54; p<0.0001). Like previous trials, there was no
significant difference in OS between the two groups. The
most common adverse effects (AEs) in the erlotinib group
were rash, diarrhea, and transaminitis.29 This was the
primary trial that demonstrated that non-Asian patients
could also benefit from upfront EGFR TKI treatment.
Erlotinib is currently approved for the treatment of meta
static NSCLC with EGFR exon 19 deletions or exon 21
(L858R) substitution mutations as first-line, maintenance,
or as second or greater line treatment after progression
following ≥1 prior chemotherapy regimen.14

Icotinib
Icotinib is another first-generation EGFR TKI that is
approved only in China for treatment of advanced
NSCLC. The approval was based on the ICOGEN study,
a randomized, double-blind phase III non-inferiority trial
that enrolled patients with advanced NSCLC who had not
responded to one or more platinum-based chemotherapy
regimens, regardless of presence of EGFR mutation.
Patients received icotinib 125 mg three times daily or
gefitinib 250 mg once daily until disease progression or
unacceptable toxicity. The PFS results deemed icotinib to
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be non-inferior to gefitinib (HR=0.84, 95% CI, 0.67 to
1.05) with a median PFS of 4.6 vs 3.4 months,
respectively.44 Given the non-inferior results when com
pared to icotinib, the CONVINCE trial further sought to
assess the efficacy and safety of first-line icotinib versus
cisplatin/pemetrexed plus pemetrexed maintenance in
EGFR positive NSCLC. Two-hundred eighty-five patients
with stage IIIB/IV lung adenocarcinoma and a positive
EGFR mutation were enrolled to receive either icotinib
or 3-week cycles of cisplatin/pemetrexed for up to four
cycles. PFS was found to be significantly longer in the
icotinib group (11.2 vs 7.9 months; HR=0.61, 95% CI,
0.43 to 0.87; p=0.006) and no significant OS differences
were observed between treatments in the overall popula
tion or in the EGFR-mutated subgroups.45
First-generation TKIs are generally considered to have
similar efficacy and toxicity profile. Some meta-analyses
have combined studies involving these agents such as one
by Lee and colleagues, who compared the OS of gefitinib
or erlotinib compared to chemotherapy for EGFR muta
tion-positive lung cancer. In this meta-analysis, the cross
over rate was 71.1% and 64.0% for chemotherapy and
EGFR TKI cohorts in patients with the exon 19 deletion,
respectively. In patients in the exon 21 L858R subgroup,
the crossover rate was 77.2% and 67.7%, respectively.46

Second-Generation EGFR TKI
Afatinib
Afatinib is a second-generation EGFR TKI that covalently
and irreversibly binds to conserved cysteine residues of
EGFR, HER2, HER4, and ErB-4’s catalytic domains. It
inhibits tyrosine kinase activity until the synthesis of new
receptors, suggesting superior EGFR inhibition compared
to the first-generation TKIs.49 In fact, afatinib was first
developed to address secondary mutations, specifically
T790M, that occur after initial treatment with front-line
EGFR TKI with activity against HER2, HER4, and EGFRmutant NSCLC. Afatinib did not have significant activity
against T790M in clinical trials but has shown significant
activity against sensitive EGFR mutations.33–38 The LUXLUNG 3 (LL3) and LUX-LUNG 6 (LL6) trials led to the
current FDA-approved indication for first-line metastatic
NSCLC with EGFR exon 19 deletion and exon 21 L858R
substitutions.34,35 In addition, afatinib is approved for
metastatic squamous lung cancer patients who progressed
after platinum-based therapy.13
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A pooled analysis of the phase III randomized LL3 and
LL6 trials demonstrated an OS benefit with afatinib com
pared to combination chemotherapy in patients with EGFR
mutation-positive metastatic NSCLC. Notably, the OS
benefit was driven by the exon 19 deletion afatinib sub
group in both trials. In LL3, the median OS was 33.3
months (95% CI, 26.8 to 41.5) in the afatinib group
compared to 21.1 months (95% CI, 16.3 to 30.7) in the
chemotherapy group in those with deletion 19 (HR=0.54,
95% CI 0.36 to 0.79; p=0.0015). In the LL6 trial, median
OS was 31.4 months vs 18.4 months in the afatinib and
chemotherapy groups, respectively (HR=0.64, 95%, CI
0.44 to 0.94, p=0.023).50 There were no significant differ
ences observed in the L858R mutation subgroup, which
underscores different biological properties and prognoses
between the different EGFR mutation subtypes.
Given the many first and second-generation EGFR
TKIs to choose from, there have been several head-tohead trials evaluating their efficacy and superiority when
compared to other TKIs. The results of the LUX-LUNG
trials demonstrate that afatinib has improved PFS com
pared to first-generation reversible TKIs in certain
settings.36,38 The LUX-LUNG 7 was an international,
multi-center Phase 2B clinical trial that randomized 319
treatment-naïve patients with stage IIIB/IV NSCLC to
afatinib or gefitinib in 1 to 1 fashion. All patients had
centrally confirmed EGFR exon 19 deletion or L858R
substitution. Median PFS was statistically significantly
longer in the afatinib arm compared to the gefitinib arm;
11.0 vs 10.9 months, respectively (HR=0.73, 95% CI, 0.57
to 0.95; p=0.017). Median time to treatment failure (TTF)
was also significantly longer in the afatinib group: 13.7
months and 11.5 months, respectively (HR=0.73, 95% CI,
0.58 to 0.92; p=0.0073). The most common AEs including
diarrhea and rash were higher in the afatinib arm, but the
frequency of discontinuation was similar between both
groups.36
LUX-LUNG 8 was another head-to-head comparison
of EGFR TKIs. This open-label, phase III trial evaluated
the efficacy of afatinib and erlotinib in patients with
advanced squamous cell lung carcinoma who progressed
after four cycles of platinum-based chemotherapy.
Although sensitizing EGFR mutations are found in less
than 5% of squamous cell cancer, previous data have
shown that these patients respond to EGFR inhibitors
irrespective of EGFR mutation status. This responsiveness
is believed to be related to the EGFR overexpression,
which occurs in up to 82% of squamous cell cancers.38
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In the LUX-LUNG 8 trial, afatinib was found to have
a modest, but statistically significant benefit over erlotinib
with PFS of 2.4 vs 1.9 months, respectively; HR=0.82
(95% CI, 0.68 to 1.00); p=0.0427 and OS of 7.9 vs 6.8
months, respectively; HR=0.81 (95% CI, 0.69 to 0.95);
p=0.0077. However, patients in the afatinib arm had more
reported AEs including diarrhea, stomatitis, and rash.
EGFR testing was not mandated for this study and thus,
was only present in six percent of the population.38 Based
on these studies, the FDA granted approval of afatinib as
front-line treatment for patients with EGFR-mutated meta
static NSCLC and for patients with metastatic squamous
NSCLC who had progressed after platinum-based
chemotherapy.13

Dacomitinib
Dacomitinib is an irreversible second-generation EGFR
TKI, which targets HER-1, HER-2, and HER-4 receptors.
Although dacomitinib exhibited potent activity in precli
nical studies in cell lines of NSCLC, it showed modest
efficacy when given to patients with advanced NSCLC
who had progressed after other therapies, including
erlotinib.51,52 Dacomitinib did not meet its primary end
point for OS in a Phase II trial, which enrolled patients
with locally advanced or metastatic NSCLC who had pre
viously received one or two systemic regimens.52 Other
trials, notably ARCHER 1050 and ARCHER 1009, have
evaluated dacomitinib’s efficacy compared to other EGFR
TKIs.39,41
The ARCHER 1009 was a phase III trial that compared
dacomitinib to erlotinib in patients who were previously
treated advanced NSCLC. Patients who had progression
after ≥1 previous regimens of chemotherapy were
enrolled. Approximately one-quarter of patients in this
study did not have an EGFR status (14%) or possessed
a mutant type (10%). The study did not meet its primary
endpoint of demonstrating significant PFS benefit when
compared to erlotinib. Median PFS was 2.6 months (95%
CI, 1.9 to 2.8) in both the dacomitinib group and erlotinib
group (stratified HR 0.941, 95% CI, 0.802 to 1.104,
p=0.229).41
Another randomized, phase III trial, ARCHER 1050
evaluated dacomitinib versus gefitinib in treatment-naïve
patients with EGFR-mutated advanced NSCLC without
central nervous system (CNS) metastases. Patients were
well balanced amongst the two groups, but of note,
seventy-five percent of patients in this study were Asian.
Dacomitinib significantly improved PFS when compared
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to gefitinib (14.7 vs 9.2 months; HR=0.59, 95% CI, 0.47 to
0.74; p<0.0001).39 Upon further follow up, OS was also
improved with dacomitinib versus gefitinib, 34.1 com
pared to 26.8 months, respectively (HR=0.760, 95% CI,
0.582 to 0.993; p=0.044). This is the first data showing
significant improvement in OS with a second-generation
EGFR TKI compared to a first-generation EGFR TKI
irrespective of type of EGFR mutation.40 Treatmentrelated AEs were higher in the dacomitinib arm compared
to the gefitinib arm. Notably, patients in the dacomitinib
group were more likely to experience diarrhea (87% vs
56%), paronychia (62% vs 20%), dermatitis acneiform
(49% vs 29%), and stomatitis (44% vs 17%). Patients in
the dacomitinib group were also more likely to experience
grade ≥3 diarrhea (8% vs 1%), paronychia (7% vs 1%),
and dermatitis acneiform (14% vs 0%).39 As a result of
this study, the FDA-approved dacomitinib for the frontline treatment in patients with EGFR mutated metastatic
NSCLC.17

Third-Generation EGFR TKI
Osimertinib
Osimertinib is an irreversible, CNS active, thirdgeneration monoanilinopyrimidine compound that is selec
tive for sensitizing EGFR and T790M resistance
mutations.53 It is currently the only third-generation
EGFR TKI that is FDA-approved for NSCLC. Although
first- and second-generation TKIs have consistently shown
superior efficacy and safety profiles compared to first-line
platinum-based chemotherapy, tumors invariably develop
acquired resistance to these agents. The T790M mutation
in exon 20 of the EGFR gene is the most commonly
acquired resistant gene mutation following secondgeneration TKIs.54
The AURA-3 trial was an open-label, phase III trial
that enrolled 419 patients with locally advanced or meta
static NSCLC with T790M mutations to evaluate the
efficacy of osimertinib to platinum-based combination
chemotherapy plus pemetrexed. The results demon
strated osimertinib’s superiority to this combination
with the median PFS being significantly longer with
osimertinib than with chemotherapy (10.1 months vs
4.4 months; HR=0.30; 95% CI, 0.23 to 0.41; p<0.001).
In addition, ORR was significantly better with osimerti
nib (71%) than with combination chemotherapy (31%).
Osimertinib also demonstrated superior efficacy in
patients with CNS metastases. In a subgroup of 144
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patients with brain metastases, the median PFS was
longer with osimertinib than the chemotherapy arm: 8.5
months vs 4.2 months, respectively (HR=0.32; 95% CI,
0.21 to 0.49).42
Given AURA-3’s positive data, osimertinib received
accelerated approval in November 2015 for patients with
T790M-positive NSCLC whose disease progressed on
first-line EGFR TKI. Osimertinib was further evaluated
as upfront therapy in patients with EGFR positive
advanced NSCLC regardless of a T790M mutation.
FLAURA was a double-blind, phase III trial that evaluated
the efficacy of osimertinib to first-generation EGFR TKIs
(gefitinib 250 mg daily or erlotinib 150 mg daily) in 556
advanced NSCLC patients with exon 19 deletion/L858R
mutations. Median PFS was significantly longer with osi
mertinib than with standard EGFR TKIs (18.9 months vs
10.2 months; HR=0.46; 95% CI, 0.37 to 0.57; p<0.001)
and the PFS benefit was seen across all subgroups.
Notably, in patients with known brain metastases, CNS
progression was significantly lower in the osimertinib arm
(6% vs 15%). The ORR was similar between both groups:
80% with osimertinib and 76% with standard EGFR TKIs
and the safety profile of these agents was similar to that of
previous EGFR trials.43
After further follow-up, patients in the osimertinib
group demonstrated an improvement in OS with
a median OS of 38.6 months compared to 31.8 months
in the first-generation EGFR TKI group (HR=0.80,
95.05% CI, 0.64 to 1.00; p=0.046). This improvement
was consistent among most predefined subgroups. After
three years of follow up, 28% and 9% of patients were still
receiving an EGFR TKI, respectively.55
Recently, results of the ADAURA study demon
strated osimertinib as a viable adjuvant treatment option
for EGFR mutated NSCLC. This was a randomized,
double-blinded, placebo-controlled phase III trial inves
tigating osimertinib vs placebo in 682 patients.
Osimertinib improved DFS by 83% vs placebo
(HR=0.17, 95% CI, 0.12 to 0.23; p<0.0001) in those
with stage II to IIIA disease. The two-year DFS rate in
this group was 90% vs 44%, respectively. When patients
with stage IB were added to the analysis, osimertinib
improved DFS by 79% (HR=0.21, 95% CI, 0.16 to 0.28;
p<0.0001). The two-year DFS rate was 89% vs 53%,
respectively.56
Table 2 enlists important clinical trials involving
first-, second- and third-generation EGFR TKIs.
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EGFR TKI Combination Treatments
There are emerging data to support the use of EGFR TKIs
in combination with other systemic therapies in the frontline setting. Gefitinib combined with carboplatin and
pemetrexed demonstrated an improvement in PFS and
OS.57–60 Noronha and colleagues investigated this combi
nation compared to gefitinib alone in advanced EGFR
mutated NSCLC. They conducted a phase III trial in 350
patients from India who were randomized in a 1:1 fashion.
A 55% reduction for risk of death was demonstrated
[HR=0.45 (95% CI, 0.31 to 0.65); p=0.001] with an esti
mated median OS of not reached compared to 17 months
(95% CI, 13.5 to 20.5 months), respectively.57 A similar
study, NEJ009 was conducted in Japan with 345 patients.
After a median follow-up time of 45 months, the median
OS with the carboplatin, pemetrexed and gefitinib combi
nation was 50.9 months (95% CI, 41.8 to 62.5) compared
to 38.8 months (95% CI, 31.1 to 47.3) in the gefitinib
alone group (HR=0.722; 95% CI, 0.55 to 0.95, p=0.021).
Quality of life observed six months or later was not dif
ferent between the two groups. Grade 3 or greater toxi
cities were higher in the combination group compared to
the gefitinib group, 65.3% vs 31.0%, respectively.58
EGFR TKIs have also been investigated in combina
tion with vascular endothelial growth factor receptors. The
RELAY trial demonstrated an improvement in PFS by
approximately 7 months when ramucirumab was added
to erlotinib when compared to erlotinib alone in EGFR
mutated NSCLC in the front-line setting. However, the
combination group experienced a higher rate of treatmentrelated adverse events compared to erlotinib alone (72% vs
54%, respectively).61
Recent studies have shown the benefit of combining
chemotherapy or vascular endothelial growth factor recep
tors with an EGFR TKI. Earlier studies did not show this
benefit in various settings, likely because the patients in
these trials did not have an EGFR mutation. Additional
combination studies with EGFR TKIs are summarized in
Table 3.62–68

EGFR TKIs Related Toxicities and Their
Management
EGFR inhibitors are generally well tolerated; however,
patients can still experience severe adverse effects affect
ing their quality of life, to an extent where the treatment
may have to be dose reduced or discontinued. Osimertinib
is usually well tolerated as compared to other TKIs, with

submit your manuscript | www.dovepress.com

DovePress

79

80

submit your manuscript | www.dovepress.com

DovePress

3

3

NEJ00226

EURTAC29

173

230

42

Chemotherapy naïve patients with stage IIIB/IV NSCLC

Treatment naïve EGFR mutated advanced NSCLC

Treatment naïve EGFR mutated advanced NSCLC

Stage IIIB/IV adenocarcinoma

3

172

FirstSIGNAL25

3

WJTOG-

adenocarcinoma and who were nonsmokers or former
light smokers

261
(EGFR

+)

Treatment naïve patients in East Asia with advanced

1217

Patient Population

or post-operative recurrence harboring EGFR mutations

3

IPASS23,27

N

340524,28

Phase

Trial

Table 2 Select Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Trials

3-week cycles of standard IV
chemotherapy

Erlotinib 150 mg/day vs

paclitaxel

Gefitinib 250 mg/day vs carboplatin plus

Gefitinib 250 mg/day vs gemcitabine plus
cisplatin

docetaxel

Gefitinib 250 mg/day or cisplatin plus

paclitaxel

Gefitinib 250 mg/day vs carboplatin plus

Intervention

18.9 vs 14.4

704 days

35

59.1

17.0

Months)

p=0.604

p=0.138

HR=1.04
(0.65–1.68);
p=0.87

HR=0.37
(0.25–0.54);
p<0.0001

19.3 vs 19.5;

p=0.483

p<0.001
9.7 vs 5.2;

HR=0.887
(0.634–1.241);

HR=0.322
(0.236–0.438);

27.7 vs 26.6;

(0.716–1.213);

(0.944–1.520);

10.8 vs 5.4;

22.3 vs 22.9;
HR=0.932

(0.883–1.775)

(0.34–0.71);
p<0.0001
5.8 vs 6.4;
HR=1.198

HR=1.252

34.8 vs 37.3;

p=0.109

HR=0.90
(0.79–1.02);

18.8 vs 17.4;

Months)

OS (Median,

HR=0.49

9.2 vs 6.3;

p<0.001

HR=2.85
(2.05–3.98);

5.5;

p<0.001 EGFRgroup: 1.5 vs

(0.36–0.64);

9.5 vs 6.3;
HR=0.48

EGFR+ group:

Months)

FollowUp
(Median,

PFS (Median,

Median

15

53 vs

vs
30.7

73.7
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84.6
vs
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3

ARCHER

1050 (Wu YL
2017)39,40

3

LUXLUNG838

452

795

319

Treatment naïve EGFR mutated advanced NSCLC

Stage IIIB/IV SCLC after progression of ≥4 cycles of
platinum-based chemotherapy

EGFR mutated stage IIIB/IV NSCLC

Afatinib 40 mg/day vs gemcitabine and

250 mg/day

Dacomitinib 45 mg/day vs gefitinib

Afatinib 40 mg/day vs erlotinib 150 mg/
day

day

Afatinib 40 mg/day vs gefitinib 250 mg/

LUNG736,37

2B

Treatment naïve EGFR mutated advanced NSCLC

EGFR mutated stage IIIB/IV NSCLC

31.1

18.4

42.6

16.6

p=0.39

p=0.001

p=0.0077

p=0.0427

p<0.0001

HR=0.59
(0.47–0.74);

vs
71.6

74.9

22 vs
11

56

70 vs

vs
23.0

66.9

22.6

56.1
vs

NR

vs
33.6

62.7

83 vs
36

(Continued)

HR=0.760
(0.582–0.993)

34.1 vs 26.8;

(0.69–0.95);

(0.68–1.00);

14.7 vs 9.2;

7.9 vs 6.8;
HR=0.81

(0.66–1.12);
p=0.258

(0.57–0.95);
p=0.017
2.4 vs 1.9;
HR=0.82

HR=0.86

HR=0.73

27.9 vs 24.5;

p=0.61

p<0.0001
11.0 vs 10.9;

HR=0.93
(0.72–1.22);

HR=0.28
(0.20–0.39);

23.1 vs 23.5;

(0.66–1.17);

(0.43–0.78);

11.0 vs 5.6;

28.2 vs 28.2;
HR=0.88

11.1 vs 6.9;
HR=0.58

(0.86–1.35);
p=0.74

HR=1.08

10.8 vs 12.0;

p=0.607

p<0.0001
3.3 vs 1.1;

HR=0.91
(0.63–1.31);

HR=0.34
(0.22–0.51);

(0.31–0.48);
p<0.0001

LUX-

364

p=0.2663

p<0.0001

26.3 vs 25.5;

(0.83–1.71);

(0.10–0.26);

11.0 vs 5.5;

22.8 vs 27.2;
HR=1.19

13.1 vs 4.6;
HR=0.16

progression after 12 weeks of treatment with erlotinib or
gefitinib
16.4

NR

28.9 vs 27.1

25.9

HR=0.38

Afatinib 40 mg/day vs up to 6 cycles of
cisplatin plus pemetrexed chemotherapy

Afatinib 40 mg/day vs placebo

cisplatin up to 4 cycles

Erlotinib 150 mg/day vs gemcitabine and

Erlotinib 150 mg/day vs gemcitabine plus
carboplatin

or 2 previous chemotherapy regimens and had disease

EGFR mutated Stage IIIB/IV NSCLC who had received 1

EGFR mutated stage IIIB/IV NSCLC

EGFR mutated stage IIIB/IV NSCLC

cisplatin for up to 6 cycles

3

LUX-

345

585

217

154

LUNG635

3

2B/3

3

3

LUXLUNG334

LUNG133

LUX-
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285

399

(0.43–0.87);
p=0.006

mg2 cisplatin plus 500 mg/m2
pemetrexed on Day 1)

11.2 vs 7.9;

p=0.13

HR=0.84
(0.67–1.05);

4.6 vs 3.4;

p=0.8854)

30.5 vs 32.1;

p=0.57

HR=1.02
(0.82–1.27);

13.3 vs 13.9;

p=0.046

p<0.001

HR=0.61

39.6

24

(0.64–1.00);

38.6 vs 31.8;
HR=0.80
(0.37–0.57);

18.9 vs 10.2;
HR=0.46

(0.23–0.41);
p<0.001

HR=0.30

NR

p=0.817

p=0.229
10.1 vs 4.4;

HR=1.079
(0.914–1.274);

7.9 vs 8.4;

Months)

OS (Median,

HR=0.941
(0.802–1.104);

week cycles of chemotherapy (75 mg/

Icotinib 125 mg three times daily vs 3

gefitinib 250 mg once daily

chemotherapy regimens with no response

EGFR mutated stage IIIB/IV NSCLC

Icotinib 125 mg three times daily vs

Previously treated with one or more platinum-based

29

8.3

7.1

Months)
2.6 vs 2.6;

Months)

FollowUp
(Median,

PFS (Median,

Median

NR

vs
27.2

27.6

80 vs
76

31

71 vs

vs 8.0

11.0

(%)

ORR

Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; SCLC, small cell lung cancer; TKI,
tyrosine kinase inhibitors.

CONVINCE45

ICOGEN

44

erlotinib 150 mg/day

Osimertinib 80 mg/day vs standard EGFR
TKI either gefitinib 250 mg/day or

3

FLAURA43
Treatment naïve EGFR mutated advanced NSCLC

plus either carboplatin or cisplatin

progression after 1st line EGFR TKI therapy

556

Osimertinib 80 mg/day vs pemetrexed

T790M-positive advanced NSCLC with disease
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150 mg/day

Dacomitinib 45 mg/day vs erlotinib

3

Locally advanced or metastatic NSCLC, progression after

Intervention

AURA342
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Patient Population

1–2 previous regimens of chemotherapy
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NEJ-00958

NEJ02664

3

3

3

Phase

Noronha
V et al57

INTACT-2

63

INTACT-162

IMPRESS

Trial

228

345

350

1037

1093

265

N

cycles vs gefitinib 250 mg/day plus gemcitabine plus cisplatin
up to 6 cycles vs placebo plus gemcitabine plus cisplatin up to

Erlotinib 150 mg/day plus bevacizumab every 21 days vs
erlotinib 150 mg/day

EGFR mutated stage IIIB/IV NSCLC

maintenance vs gefitinib 250 mg/day

nonsquamous NSCLC

Chemotherapy naïve patients with

Gefitinib 250 mg/day plus carboplatin plus pemetrexed for up
to 6 cycles, followed by gefitinib plus pemetrexed

Gefitinib 250 mg/day plus pemetrexed 500 plus carboplatin
for 4 cycles vs gefitinib 250 mg/day

Chemotherapy naïve patients with
EGFR mutated stage IIIB/IV or relapsed

Chemotherapy naïve patients with
EGFR mutated advanced NSCLC

cycles vs gefitinib 250 mg/day plus paclitaxel plus carboplatin

unresectable stage III/IV NSCLC

up to 6 cycles vs placebo plus paclitaxel plus carboplatin up to
6 cycles

Gefitinib 500 mg/day plus paclitaxel plus carboplatin up to 6

Chemotherapy naïve patients with

6 cycles

Gefitinib 500 mg/day plus gemcitabine plus cisplatin up to 6

unresectable stage III/IV NSCLC

Gefitinib 250 mg/day plus cisplatin plus pemetrexed vs
placebo plus cisplatin plus pemetrexed

Intervention

Chemotherapy-naïve patients with

progression on gefitinib

Chemotherapy naïve patients with
EGFR mutated advanced NSCLC with

Patient Population

Table 3 Select Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Combination Trials

12.4

45.0
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15.9

11.2
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(0.31–0.65);
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p=0.016

HR=0.605
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NR
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16.9 vs 13.3;

(0.55–0.95);

(0.39–0.62);

50.9 vs 38.8;
HR=0.722
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(0.39–0.66);

20.9 vs 11.9;
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Not reached
vs 17.0;

9.9; p=0.6385

8.7 vs 9.8 vs
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72 vs

p<0.001

84 vs
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p=0.01

75.3 vs
62.5;

28.7

30.4 vs
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50.3 vs

p=0.76

32 vs
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(%)
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OS (Median,

(0.65–1.13);

5.4 vs 5.4;
HR=0.86

(Median,
Months)

FollowUp
(Median,

PFS

Median

Dovepress
Lee et al

submit your manuscript | www.dovepress.com

DovePress

83

84

DovePress

submit your manuscript | www.dovepress.com

3

1059

1172

579

449

636

N

Treatment naïve patients with stage
IIIB/IV NSCLC

recurrent or metastatic NSCLC

unresectable, locally advanced,

Chemotherapy naïve patients with

regimen

non-adenocarcinoma NSCLC who had
previously received ≥1 platinum-based

Stage IIIB/IV or recurrent disease with

Treatment naïve patients with EGFR
mutated stage IV NSCLC

followed by maintenance erlotinib 150 mg/day

Erlotinib 150 mg/day plus carboplatin plus paclitaxel vs
placebo plus carboplatin plus paclitaxel

gemcitabine plus cisplatin

Erlotinib 150 mg/day plus gemcitabine plus cisplatin vs

erlotinib 150 mg/day

Erlotinib 150 mg/day plus figitumumab every 21-day cycle vs

Erlotinib 150 mg/day plus ramucirumab every 14 days vs
erlotinib 150 mg/day

erlotinib 150 mg/day

line chemotherapy

Erlotinib 150 mg/day plus bevacizumab every 21 days vs

were recurrent or refractory to first

Intervention

Patients with advanced NSCLC who

Patient Population
Months)

Up
(Median,

NR

NR

NR

20.7

19.0

83% vs 79%

p<0.0001

p=0.36

5.1 vs 4.9;
HR=0.937;

(0.86–1.11);
p=0.74

HR=0.98

5.5 vs 5.7;

p=0.43

HR=1.08
(0.90–1.29);

p=0.95

(0.86–1.16);

10.6 vs 10.5;
HR=0.995

(0.90–1.23);
p=0.49

HR=1.06

10.0 vs 10.3;

p=0.35

HR=1.09
(0.91–1.31);

5.7 vs 6.2;

2-year OS:

(0.46–0.76);

2.1 vs 2.6;

1-year OS:
93% vs 94%

(0.80–1.18);
p=0.7583

HR=0.97

9.3 vs 9.2;

Months)

OS (Median,

19.4 vs 12.4;
HR=0.59

(0.52–0.75)

HR=0.62

3.4 vs 1.7;

(Median,

Follow-

Months)

PFS

Median

Abbreviations: EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; NR, Not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
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minimal grade 3 or higher toxicities.43 Along with the
tumor cells, EGFR is also expressed in healthy epithelial
cells, mainly in the skin and gastrointestinal (GI) tract.69,70
EGFR TKIs inhibit overexpressed EGFR in both cancer
cells and in normal cells. This inhibition results in release
of inflammatory cytokines, which subsequently leads to
cutaneous and GI toxicities.70 Cutaneous AEs can affect
20%-89% of patients.30,34,71 These AEs may be mild to
moderate but can be severe in up to 18% of patients, with
GI AEs affecting 21–95% of patients.30,34,71,72 A survey of
110 oncologists conducted by Boone et al showed that
76% of patients experienced treatment interruptions and
32% of patients discontinued their treatment due to skin
rash. Furthermore, a 10–50% dose reduction was made in
60% of patients due to cutaneous toxicities. The survey
also showed that EGFR TKI-related diarrhea was asso
ciated with lethargy and sleep interruptions, affecting
patient’s quality of life.73 Therefore, management of AEs
is imperative to ensure treatment adherence and to
improve quality of life.

Cutaneous Toxicities of EGFR TKIs
Various types and grades of cutaneous toxicities are seen
in patients taking EGFR TKIs. This is mainly due to the
inhibition of healthy EGFR found in the epidermis of skin,
which plays a crucial role in epithelial maintenance. The
earliest and most commonly reported AE is an acneiform
rash (also termed as papulopustular rash), which occurs in
90% of patients as early as 1–2 weeks of treatment, and is
common in the sebaceous epithelium or glands.30,34,71,74-76
Osimertinib has shown to have a lower incidence of over
all rash as well as grade ≥3 rash when compared to firstgeneration-EGFR TKIs.43 The rash usually progresses
through four distinct phases, starting from dysesthesia,
erythema and edema, followed by erythematous papules
and pustules, followed by purulent crusts at 3–6 weeks and
telangiectasia.75,76 There are several proposed systems for
grading, but the most commonly used system is the NCI
CTCAE (National Cancer Institute Common Terminology
Criteria for Adverse Events) version 4.03, which classifies
the rash in 5 grades (Table 4).77,78 The eruptions may
decrease over 3–4 weeks despite the continuation of TKI
but may persist as mild erythema or follicular papules
throughout the course of treatment.74,78
Xerosis is the second most reported AE which occurs
in almost 50% of patients, usually after 30–50 days of
treatment.30,34,71,74,78 EGFR TKIs alter the epidermal bar
rier leading to dry skin.74 Xerosis presents as dry, scaly
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patches, but may advance to painful fissuring and xerotic
eczema with risk of secondary infections with staphylo
coccus aureus or herpes simplex virus. It usually has
widespread involvement and can affect any part of the
body.74,78 NCI CTCAE version 4.03 classifies xerosis in
3 grades (Table 4).
Paronychia is the other cutaneous AE, which occurs in
5–20% of patients, usually after 4 to 8 weeks of
treatment.30,34,71,74,78 This occurs due to the inhibition of
keratinocytes in the nail matrix due to TKIs. It usually
presents as painful periungual inflammation, but in severe
cases can cause periungual abscess and pyogenic granu
loma. It can also lead to onycholysis or onychodystrophy.
It is graded per CTCAE 4.03 guidelines (Table 4).74,78
Abnormalities of hair growth can sometimes occur
presenting as hirsutism, hypertrichosis and trichomegaly.
This usually occurs after 2–5 months of treatment and is
due to an increased terminal differentiation caused by
EGFR inhibition. If it involves the eyelashes, conjunctivi
tis, corneal irritation and ulceration can occur.74,78
Scarring or non-scarring alopecia is unusual, but can affect
5–6% of patients and develops after 2–4 months of treat
ment. Scalp inflammation and extensive scalp pustules are
also uncommon but can occur.74

Management of Cutaneous Toxicity
Since cutaneous toxicities are almost universally antici
pated, all patients starting on EGFR TKIs should be edu
cated about general skincare measures. This includes skin
cleansing and washing with lukewarm water and with the
use of soap/alcohol-free products. It is also recommended
to use thick alcohol-free emollients and sunscreen lotion
with SPF ≥ 25.79

Acneiform Rash
There is a lack of evidence-based guidelines from prospec
tive, randomized controlled trials, and hence, the manage
ment of the rash differs by clinician.79 In general, the
management of the rash depends on the grade.
Clindamycin gel 1% twice a day with topical hydrocorti
sone cream 2.5% is recommended for grade 1 rash and
TKI dose adjustment is not required. For grade 2 rash, oral
anti-inflammatory antibiotics such as doxycycline 100 mg
twice daily or minocycline 100 mg daily are recom
mended, in addition to a topical steroidal cream. Dose
adjustment is not required. The rash should be monitored
carefully, and clinicians should be wary of the signs of
bacterial super-infection. Grade 3 or higher rash warrants
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Table 4 National Cancer Institute Common Terminology Criteria for Adverse Events V5.0 Grading Criteria for Common Epidermal
Growth Factor Receptor Tyrosine Kinase Inhibitors Induced Toxicity77
Grade

Cutaneous Toxicities

Xerosis

Paronychia

Diarrhea

1

Papules and/or pustules covering <10%

Dry skin covering <10%

Nailfold edema and/or

Increase of less than 4 stools

BSA, with or without symptoms of

BSA, with no associated

erythema with cuticle

per day over normal

pruritus or tenderness.

erythema or pruritus.

disruption.

Papules and/or pustules covering

Dry skin covering

Painful nail fold bogginess

Increase of 4–6 stools per day

10–30% BSA with or without symptoms
of pruritus or tenderness; with

10–30% BSA with
erythema or pruritus

and/or discharge with
onycholysis.

over normal, limiting
instrumental ADL

psychological impact and limiting

and limiting instrumental

instrumental ADL.

ADL.

Papules and/or pustules covering >30%
BSA with or without symptoms of

Dry skin covering >30%
BSA with pruritus and

Ingrown nails with intense
pain; pyogenic granuloma

Increase of 7 or more stools
per day over normal; or

pruritus or tenderness; limiting self-care

limiting self-care ADL

and/or exuberant

incontinence; hospitalization

periungual granulation
tissue.

indicated; limited self-care ADLs.

2

3

ADL associated with local superinfection
for which oral antibiotics is indicated.
4

Papules and/or pustules covering any
percentage of BSA with or without

Life threatening consequences,
urgent intervention required.

symptoms of pruritus or tenderness;
associated with extensive superinfection
for which intravenous antibiotics is
indicated; can have life threatening
consequences.
5

Death

Death

Notes: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Abbreviations: ADL, activities of daily living; BSA, body surface area.

dermatology referral. In addition to oral antibiotics and
topical steroids, oral steroids (prednisone 0.5 mg/kg/day
for 5 days) are recommended. Occasionally, low dose
isotretinoin is used, but under the supervision of
a dermatologist. TKI therapy is interrupted until the rash
is grade ≤2, and a reduced dose of TKI is resumed
(Table 5).74,79
Secondary bacterial infection can follow cutaneous
toxicities. If superinfection is suspected, antibiotics like
cloxacillin or cephalexin are recommended for a week
before the initiation of prophylactic anti-inflammatory
antibiotics. Potassium permanganate compresses for
a few days, in addition to a topical steroid-antibiotic
cream, helps the infected lesions heal faster.74

Xerosis/Pruritus
Symptomatic treatment of xerosis includes skincare with
oil-in-water moisturizing creams or emollients like petro
leum jelly, Eucerin, Aquaphor or zinc oxide (30%).
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Eczematous lesions can be treated with a topical steroidal
cream for 1–2 weeks. Patients with pruritis are treated with
topical or systemic steroids, anti-histamines, or GABA
agonists.74,79 For grade 3 xerosis, TKI treatment should
be interrupted and resumed at a lower dose once the
xerosis is grade ≤2. Dermatology referral is recommended
for grade 3 xerosis or if there is no improvement with
conventional methods.

Paronychia
All patients starting TKIs should be educated about nail
hygiene. Aggressive manicures/pedicures, strong irri
tants, and prolonged exposure to water or hot water
should be avoided.80 Paronychia requires treatment
with topical steroids, antimicrobials, and silver nitrate.
Soaking fingers or toes in white vinegar for 15 minutes
every day maybe useful. Grade 1 lesions are treated
with topical steroids like betamethasone valerate 0.1%
twice per day. Along with topical steroids, grade 2
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Table 5 Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Induced Acneiform Rash (Reactive
Treatment)77
Grade

Treatment of Rash

TKI Treatment

1

Topical anti-inflammatory antibiotics 1% Clindamycin BID. Topical steroids

Continue treatment at the current dose and monitor for

like 2.5% hydrocortisone is considered, especially if the rash is itchy.

bacterial super-infection or worsening of the rash.

Oral anti-inflammatory antibiotics like Minocycline 100 mg daily or

Continue treatment at the current dose and monitor for

Doxycycline 100 mg BID with topical steroid cream (hydrocortisone 2.5%,

bacterial super-infection or worsening of the rash.

2

desonide, alclometasone 0.05% to the face and neck or fluocinonide 0.05%
cream to chest and back)
≥3

Dermatology referral.

Interrupt the treatment.

Oral prednisone (0.5 mg/kg/day X 5 days) in addition to oral anti-

Restart the TKI at a reduced dose once the rash is ≤ 2.

inflammatory antibiotics like minocycline 100 mg daily or doxycycline 100 mg
BID with topical steroid cream.

Discontinue the TKI, if the rash does not improve.

Low dose isotretinoin (20 to 30 mg/day) is also considered.
Abbreviation: TKI, tyrosine kinase inhibitors.

Table 6 Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Induced Diarrhea77
Grade

Treatment of Diarrhea

TKI Treatment

1

Start non-pharmacologic strategy.

Maintain current dose of TKI.

Start Loperamide (4 mg, followed by 2 mg every 2–4 hours or
after every loose stool until there is no bowel movement for
12 hours).
2

As grade 1. -fAdd diphenoxylate/atropine (2 tablets every 6
hours) or Codeine (30 mg every 4 hours).

Maintain current dose of TKI. If diarrhea does not respond to
loperamide at 48 hours, TKI should be temporarily discontinued
until diarrhea returns to grade 1, after which TKI is resumed as:
Erlotinib: Lower dose by 50 mg to a minimum of 50 mg.
Afatinib: Lower dose by 10 mg to a minimum of 20 mg.
Gefitinib: Resume at original dose.

≥3 or with

As grade 2.

Interrupt the treatment.

complication

Octreotide (100 to 150 mcg subcutaneous three times a day)

Resume TKI as above once diarrhea is grade 1 or lower.

or tincture of opium is added if diarrhea continues.
Octreotide is titrated up to 2000 mcg three times a day based

If diarrhea does not reach grade 1 or lower despite supportive
measures and holding TKI by 14 days, permanently discontinue

on the response.

TKI.

Endoscopic evaluation is considered, if diarrhea continues
despite use of loperamide and octreotide for 24 hours.
Abbreviation: TKI, tyrosine kinase inhibitors.

lesions require topical antimicrobials. Exuberant granu
lation tissue is treated with silver nitrate and dermatol
ogy referral is recommended if the lesions do not heal.
If the granulation does not respond to topical agents,
electrodesiccation or carbon dioxide laser ablation is
usually performed. Secondary prophylaxis with doxycy
cline is recommended.74,80 Grade 3 lesions will require
treatment interruptions and TKI should be resumed at
a lower dose once the lesion is grade ≤2.

Lung Cancer: Targets and Therapy 2020:11

Gastrointestinal Toxicities of EGFR
TKIs
Various types of GI toxicities are seen in patients taking
EGFR TKIs, mainly due to the inhibition of normal EGFR
found in squamous epithelium in the tongue, esophagus
and GI tract.71 The most commonly reported GI AE is
diarrhea.47,79 Diarrhea is thought to occur not only due to
inhibition of normal EGFR but also due to excess chloride
secretion caused by inhibition of calcium-dependent
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chloride transport.81 NCI CTCAE v4.03 classifies diarrhea
in 5 grades (Table 4).
Oral mucositis and stomatitis are also reported with
EGFR TKIs, which can be debilitating. Mucositis is
usually mild but can be painful and severe with extensive
erythema causing aphthous-like stomatitis. Grade 1 is
usually asymptomatic or mildly symptomatic. Grade 2 is
associated with moderate pain, which does not interfere
with eating or drinking. Grade 3 is associated with severe
pain that interferes with intake of food or drink. Grade 4 is
considered life-threatening and grade 5 is death.

Management of Gastrointestinal
Toxicities
Diarrhea
Prior to TKI initiation, educating patients regarding the
incidence of diarrhea is of utmost importance. Patients
should call their provider immediately with increased fre
quency or changes in bowel habits. Management of TKI
diarrhea includes non-pharmacological and pharmacologi
cal methods.

Non-Pharmacologic Strategy
At the first instance of diarrhea, patients should discon
tinue any baseline use of stool softeners and laxatives.
Patients should be educated on adequate fluid intake and
dietary modifications with any changes in bowel habits.
Patients should maintain hydration with at least 3–4 liters
of fluids daily, including fluids with salt and sugar to avoid
electrolyte imbalances. Prophylactic dietary changes are
not recommended. However, the BRAT (banana, rice,
applesauce, toast) diet is recommended for patients with
diarrhea. Vegetables, fibrous foods and legumes should be
reduced. Spicy and fried foods should be avoided.82

Pharmacologic Measures
Loperamide is the mainstay of treatment for diarrhea
and should be started immediately at the onset of diar
rhea. Patients with grade 1 and 2 diarrhea can be man
aged at home, but hospitalization may be required for
diarrhea which is grade 3 or higher. Infective causes for
diarrhea should be excluded. The maximum daily
recommended dose for loperamide is 16 mg (4 mg
immediately after symptoms begins, followed by 2 mg
every 2–4 hours depending on the frequency of diar
rhea). Diphenoxylate–atropine or codeine may be used
in conjunction with loperamide if diarrhea is not
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controlled with loperamide alone. The maximum daily
recommended dose for diphenoxylate 2.5 mg–atropine
0.025 mg is 20 mg (of diphenoxylate) (taken as 2 tablets
every 6 hours) and for codeine is 120 mg (taken as
30 mg every 4 hours). Occasionally, octreotide or tinc
ture of opium is required for grade 3 or higher diarrhea.
Octreotide is initiated at 100 to 150 mcg subcutaneously
three times a day, but the dose can be titrated up to
2000 mcg every 8 hours based on the response.82,83 TKI
treatment is continued for grade 1 and 2 diarrhea. TKI is
temporarily discontinued for grade 2 diarrhea if the
symptoms are not improved within 48 hours of using
loperamide. For grade 3 or higher diarrhea, TKI is
interrupted until diarrhea reaches grade 1.
After interruption, erlotinib and afatinib are recom
mended to be resumed at a lower dose, but gefitinib is
resumed at the original dose. The recommendation is to
reduce the dose of erlotinib by 50 mg to a minimum dose
of 50 mg and to reduce the dose of afatinib by 10 mg to
a minimum dose of 20 mg (Table 6).82

Mucositis/Stomatitis
A routine follow-up with the dentist prior to starting treat
ment, to diagnose and manage any underlying dental
issues, is beneficial. It is important to educate the patient
on dental and oral hygiene, including the use of a softbristle brush, floss, sodium-bicarbonate and alcohol-free
mouthwash.84 For general mouth sensitivity, patients can
gargle with benzydamine rinse, three times daily as
needed. Ice chips or flavored popsicles can be used to
numb the mouth and to temporarily ameliorate any symp
toms. Acidic, spicy, salty, or coarse food should be
avoided.74,83,84
Triamcinolone in dental paste 2–3 times as needed is
used for grade 1 mucositis. Oral erythromycin
(250–350 mg daily) or minocycline (50 mg daily) is
added for grade 2 mucositis. For grade 3 or higher muco
sitis, clobetasol ointment is used in dental paste along with
erythromycin (500 mg daily) or minocycline (100 mg
daily). TKI is not interrupted and dose reduction is not
required for grade 1 and 2 mucositis. For grade 3 or higher
mucositis, TKI is discontinued temporarily until it heals to
grade 2 or less. At that point, TKI is reintroduced, usually
at the initial dose.84

Lung Toxicity with EGFR TKI
Although uncommon, pulmonary toxicity is seen with EGFR
TKI, and is higher in smokers, patients with underlying lung
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Previously treated with osimertinib and second line platinum and pemetrexed

II

III

I

II

I

I/II

III

II

NCT04335292
(OCELOT)93

NCT0423983394

NCT0325508395

NCT0394070396

NCT0359951897

NCT0344641798

NCT04351555
(NeoADAURA)99

NCT01532089100

EGFR mutated advanced NSCLC who have progressed first or second line EGFR
TKI
EGFR mutated stage III unresectable NSCLC

III

II

NCT02864251
(CheckMate722)103

NCT02347839
(NEGOTIATE)104

EGFR mutated advanced NSCC NSCLC who have progressed on EGFR TKI and
chemotherapy

II

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated metastatic NSCLC

EGFR mutated resectable NSCLC

EGFR mutated advanced NSCLC who have progressed on EGFR TKI

EGFR mutated metastatic or unresectable NSCLC having acquired resistance to
EGFR TKI

MET Amplified, EGFR mutated advanced or metastatic NSCLC having acquired
resistance to prior EGFR TKI

EGFR mutated locally advanced or metastatic NSCLC who have progressed on an
EGFR TKI

NCT03382795102

NCT03909334

II

EGFR mutated advanced NSCLC receiving afatinib as first line treatment

III

NCT0420678792

101

EGFR mutated NSCLC in patients with progressive disease on osimertinib

II

NCT04099836
(TOP 1901)91

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

III

NCT04035486
(FLAURA2)90

Patient Population

Phase

Protocol Name

Neoadjuvant gefitinib followed
by surgery + gefitinib

Nivolumab + chemotherapy or
nivolumab + ipilimumab

Gefitinib or erlotinib

Osimertinib + ramucirumab

Erlotinib + bevacizumab

Osimertinib + pemetrexed +
cisplatin or carboplatin

ZN-e4

DS-1205c + gefitinib

Tepotinib + osimertinib

DS-1205c + osimertinib

SH-1028

Osimertinib

Sequential afatinib treatments
(observatory)

Atezolizumab + bevacizumab

Osimertinib + pemetrexed +
cisplatin or carboplatin

Treatment Regimen

Table 7 Ongoing and Future Clinical Trials for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

37

580

69

150

88

351

140

63

90

13

240

200

825

39

586

Target
Sample
Size (n)

Resectability
rate

PFS

ORR

PFS

PFS

MPR

Safety

Safety

Safety, ORR

Safety

PFS

ORR

TOT

ORR

PFS

Primary
Outcomes
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Perioperative
complications, EFS, OS

OS, ORR, DOR

PFS, OS, safety

ORR, DCR, OS, safety

OS, ORR, safety

PCR, EFS, OS, DFS,
QOL

Safety

PD, PK, ORR, DOR,
DCR, PFS, OS

DOR, DCR, PFS, OS,
QOL

PD, PK, ORR, DCR, PFS,
OS

ORR, DOR, DCR, OS,
safety

PFS, DOR, DCR, OS,
TTF, QOL

OS, PFS, ORR, DCR

PFS, OS, safety

OS, ORR, DOR, DCR

Secondary Outcomes
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90
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I/II

NCT02954523121

I/II

NCT03807778116

I/II

I/II

NCT03502850115

NCT03201146120

III

NCT03802240
(ORIENT-31)114

I

I

NCT02973763113

NCT04153799119

II

NCT03904823112

II

II

NCT03126799111

NCT03769103118

II

NCT03861156110

III

III

NCT03532698109

NCT03799094117

III

NCT04248829
(LASER301)108

NCT04085315

I

IB

NCT04141644106

107

III

Phase

NCT01996098
(ICTAN)105

Protocol Name

Table 7 (Continued).

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated metastatic NSCLC with BM

EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated, exon 20 locally advanced or metastatic NSCLC who have
progressed on EGFR-TKI

EGFR mutated locally advanced or metastatic NSCLC who have progressed on
EGFR-TKI

EGFR mutated locally advanced or metastatic non-squamous NSCLC who have
progressed on EGFR-TKI

EGFR mutated advanced NSCLC who have progressed on an EGFR TKI and have
a T790M mutation

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated advanced or metastatic NSCLC

EGFR mutated locally advanced or metastatic NSCLC who have progressed on
EGFR TKI and have a T790M mutation

EGFR T790M mutated metastatic NSCLC who have progressed on osimertinib

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated metastatic NSCLC who have progressed on or stable on
osimertinib

EGFR mutated locally advanced or metastatic NSCLC stable on osimertinib

EGFR mutated stage IIA-IIIA unresectable NSCLC

Patient Population

Osimertinib + dasatinib

Apatinib + pemetrexed +
cisplatin or carboplatin

CXCR5 Modified EGFR CAR-T

Osimertinib + SRS

Vitamin C + EGFR TKI

TAK-788

ASK120067

Sintilimab ± IBI305 +
pemetrexed + cisplatin

Alflutinib

Famitinib + HS-10,296

Erlotinib + bevacizumab

D-0316

Osimertinib + aspirin

Lazertinib

Alisertib + osimertinib

Osimertinib + ipilimumab

Icotinib following chemotherapy

Treatment Regimen

10

48

11

76

150

63

135

600

14

58

128

286

100

380

36

26

318

Target
Sample
Size (n)

Safety

ORR

Safety, ORR

CNS PFS

PFS

Safety

ORR

PFS

Safety

ORR

PFS

ORR

ORR

PFS

Safety

Safety

DFS

Primary
Outcomes

PK, PD, PFS, OS, DOR

PFS, DCR, OS

PK, PD, DOR, PFS

CNS OS, time to SRS/
WBRT, OS, QOL

OS, QOL

PK, PD, ORR, DOR,
DCR, PFS, OS, QOL

Safety, PFS, DOR, DCR,
OS, PK, PD

OS, ORR

PK, PD, ORR, DOR, PFS

DOR, DCR, PFS, safety

ORR, OS

PFS, OS, DOR, DCR,
CNS response

DCR, TTP, DOR

ORR, DOR, DCR, OS,
QOL, CNS responses

ORR, DOR, DCR, PFS,
OS, CNS DCR

ORR, PFS, OS

OS, safety, QOL

Secondary Outcomes
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II

II

I/IIA

II

NCT03811054129

NCT03434418130

NCT04036682131

NCT04426825132

NCT04148898136

II

IB/II

III

NCT04129502128

NCT01982955
(INSIGHT)135

I

NCT02789345127

II

EGFR mutated stage III unresectable NSCLC

III

NCT03521154
(LAURA)126

NCT03091491134

EGFR mutated advanced or metastatic NSCLC who have progressed on
osimertinib

I

NCT02503722125

II

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC who have
disease control after an 8-week lead-in with erlotinib

II

NCT01897480
(Balise)124

NCT02820116133

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

II

NCT02716311
(ACE-Lung)123

EGFR mutated advanced or metastatic NSCLC with leptomeningeal metastasis

EGFR mutated advanced or metastatic MET positive NSCLC who have progressed
on an EGFR TKI

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

EGFR mutated stage IIIA - IIIB NSCLC

EGFR mutated advanced or metastatic NSCLC previously treated with an EGFR
TKI

EGFR mutated, exon 20 locally advanced or metastatic NSCLC previously treated
with platinum based chemotherapy

Treatment naïve uncommon EGFR mutated locally advanced or metastatic NSCLC
(exon 18 G719X, exon 20 S768I, or exon 21 L861Q)

EGFR mutated advanced or metastatic NSCLC with slow progression on an EGFR
TKI

Treatment naïve EGFR mutated, exon 20 locally advanced or metastatic NSCLC

EGFR mutated advanced NSCLC who have progressed on an EGFR TKI and have
a T790M mutation

EGFR mutated, exon 20 locally advanced or metastatic NSCLC

II

NCT03727724
(AFACET)122

Osimertinib + bevacizumab

Tepotinib + gefitinib

Nivolumab + ipilimumab

Neoadjuvant icotinib

Atezolizumab + bevacizumab

CLN-081

Osimertinib

Apatinib + EGFR-TKI

TAK-788

Osimertinib + ramucirumab or
necitumumab

Osimertinib following
chemoradiation

Sapanisertib + osimertinib

LY2875358 + erlotinib

Afatinib + cetuximab

Afatinib + cetuximab

80

70

184

67

60

80

37

60

318

74

200

36

150

118

37

CNS PFS,
ORR

Safety

ORR

CRR

PFS

Safety

ORR

ORR

PFS

Safety

PFS

Safety

PFS

TTF

DCR
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CNS OS, PFS, safety

PFS, OS, ORR, DCR, PK,
PD, QOL

PFS, DOR, OS, safety

ORR, DCR, PFS, OS,
safety

ORR, DOR, OS, safety

ORR, DOR, DCR, PFS,
OS, PK, PD

PFS, safety, OS

DCR, OS, PFS, safety

ORR, OS, DOR, DCR,
QOL

PK, PD, ORR, DCR,
DOR, PFS, OS

CNS PFS, OS, ORR,
DOR, DCR, safety

PK, PD, ORR, DCR, PFS

ORR, DOR, OS, PK

Safety, ORR, OS, PFS

ORR, safety, DOR, PFS,
OS

Dovepress
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II

II

II

NCT01553942
(ASCENT Trial)151

NCT03823807152

II

NCT04233021
(ORBITAL)147

NCT03392246150

III

NCT03428022
(AFLC)146

II

II

NCT03396185145

NCT04405674149

EGFR mutated advanced or metastatic NSCLC with brain or leptomeningeal
metastasis

II

NCT04425681
(OWBLM)144

III

EGFR mutated advanced or metastatic NSCLC with slow progression on an EGFR
TKI

I/II

NCT03122717143

NCT04143607148

EGFR mutated stage IIIA-IIIB NSCLC

I

NCT03755102142

EGFR mutated advanced NSCLC who have progressed on an EGFR TKI and have
a T790M mutation

Treatment naïve EGFR mutated stage III NSCLC

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCC NSCLC who have progressed on an
EGFR TKI

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCLC with leptomeningeal metastasis

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on
osimertinib

EGFR/HER2 mutated locally advanced or metastatic NSCLC (also includes exon
20)

I/II

NCT02716116141

EGFR mutated stage II–IIIA (N1-N2) NSCLC

III

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

Treatment naïve EGFR mutated locally advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Patient Population

NCT01405079140

NCT04206072

II/III

II/III

NCT02438722138

139

I

Phase

NCT03603262137

Protocol Name

Table 7 (Continued).

SH-1028

Afatinib + chemoradiation

Osimertinib + selumetinib

Tislelizumab + carboplatin +
nab-paclitaxel

ASK120067

Osimertinib

Apatinib + EGFR-TKI

Icotinib following
chemoradiation

Osimertinib + bevacizumab

Osimertinib + gefitinib

Dacomitinib + osimertinib

TAK-788

Gefitinib

D-0316

Afatinib + cetuximab

SH-1028

Treatment Regimen

300

30

25

66

334

113

54

30

20

64

24

306

222

360

174

85

Target
Sample
Size (n)

ORR

ORR

Best ORR

PFS

PFS

ORR

PFS

RFS

CNS PFS,
ORR

Safety

ORR

ORR

DFS

PFS

PFS, OS

Safety, PK,
PD

Primary
Outcomes

Safety, PK, PD, PFS,
DOR, DCR, OS

PFS, safety, DCR

PFS, OS, safety

ORR, DCR, OS, DOR

ORR, DOR, DCR, OS

OS, PFS, safety, QOL

OS, ORR

OS, safety

CNS OS, PFS, safety

ORR, PFS, OS

PFS, OS

PK, PD, DOR, DCR, PFS,
OS

OS, safety, QOL

ORR, DOR, DCR, OS,
CNS PFS, safety

ORR, TTF, safety

ORR, PFS, DCR, OS

Secondary Outcomes
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II

I/II

II

II

I

NCT0400783516

NCT03831932162

NCT00977470163

NCT03341494164

NCT02496663165

III

II/III

NCT03653546160

NCT03983811169

III

NCT02824458159

I/II

I

NCT02520778158

NCT02917993168

I

NCT01859026157

III

II

NCT03066206156

NCT04181060167

II

NCT02098954155

II

II

NCT04358562154

NCT01746251166

I

NCT04204473153

EGFR mutated Stage IIB-IIIA NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Treatment naïve EGFR mutated advanced or metastatic NSCLC

EGFR mutated Stage I–III NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Treatment naïve EGFR mutated advanced or metastatic NSCLC

Treatment naïve EGFR mutated advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Treatment naïve EGFR mutated advanced or metastatic NSCLC with CNS
metastases

Treatment naïve EGFR mutated advanced or metastatic NSCC NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

EGFR or KRAS mutated advanced or metastatic NSCLC

EGFR mutated, exon 20 locally advanced or metastatic NSCLC

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

EGFR mutated advanced NSCC NSCLC with uncleared plasma ctDNA EGFR
mutation after progression on gefitinib

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Icotinib + chemotherapy
(adjuvant)

Itacitinib + osimertinib

Osimertinib + bevacizumab

Afatinib (adjuvant)

Osimertinib + necitumumab

Gefitinib + thalidomide

Erlotinib + hydroxychloroquine

CB-839 + osimertinib

Anlotinib + EGFR TKI

AZD3759

Gefitinib + apatinib

Osimertinib + navitoclax

MEK162 + erlotinib

Poziotinib

Erlotinib + gemcitabine +
cisplatin

Gefitinib + anlotinib

TY-9591

174

59

300

92

100

128

76

53

120

432

346

50

43

80

40

240

126

DFS

Safety, ORR

PFS

RFS

Safety

PFS

PFS

Safety, ORR

PFS

PFS

Safety, PFS

Safety

Safety

ORR

PFS

PFS

Safety, ORR

Safety

(Continued)

PK, PD, PFS, OS

OS, ORR, time to CNS
metastases, safety

Safety, OS

ORR, PFS, DCR, PK, PD

ORR, OS

Safety, ORR, OS

PFS,OS, PK, PD

ORR, DCR, OS, safety

CNS PFS, ORR, DCR,
DOR, OS

OS, ORR, DCR, DOR,
QOL. PK, PD

PK, PD, ORR

PFS, OS

DCR, PFS, OS, DOR,
safety

OS, ORR

OS, ORR, safety

PK, PD, PFS, DOR
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EGFR mutated Stage III resectable NSCLC

Treatment naïve advanced or metastatic NSCLC

II

I

I

II

II

II

IB

NCT04042558171

NCT02609776
(CHRYSALIS)172

NCT03234712173

NCT01470716174

NCT03778229
(SAVANNAH)175

NCT04201756176

NCT03623750
(EPICAL)177

Afatinib + EGF-PTI +
cyclophosphamide

Afatinib (neoadjuvant)

Osimertinib + savolitinib

Erlotinib (neoadjuvant)

ABBV-321

Lazertinib

Carboplatin + Pemetrexed +
Atezolizumab + Bevacizumab

U3-1402

Treatment Regimen

30

47

192

26

120

460

149

198

Target
Sample
Size (n)

Safety

ORR

ORR

PFS

PK, PD

Safety, ORR

ORR

Safety, ORR

Primary
Outcomes

Clinical outcomes

DFS, OS, PFS, safety,
QOL

PFS, QOL, OS, safety,
DOR

ORR, OS, safety

PFS, DOR, DCR, OS,
ORR

PK, PD, PFS, OS

PFS, OS, DOR

PK, PD, DCR, DOR, PFS,
OS

Secondary Outcomes

Abbreviations: BM, brain metastases; CAR-T, chimeric antigen receptor autologous T-Cells; CNS, central nervous system; CRR, complete resection rate; DCR, disease control rate; DFS, disease-free survival; DOR, duration of
response; EGF-PTI, EGF pathway targeting immunization; EGFR, epidermal growth factor receptor; EFS, event-free survival; MET, mesenchymal-epithelial transition; MPR, major pathological response; NSCC, non-squamous cell
carcinoma; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PCR, pathological complete response; PD, pharmacokinetics; PK, pharmacodynamics; PFS, progression-free survival; QOL, quality of life;
SRS, stereotactic radiosurgery’ TKI, tyrosine kinase inhibitor; TOT, time on treatment; TTP, time to progression; TTF, time to treatment failure; WBRT, whole brain radiotherapy.

EGFR mutated advanced or metastatic NSCLC who have progressed on
osimertinib

EGFR mutated Stage II–IIIA NSCLC

Advanced solid tumors with overexpression EGFR

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

Advanced or metastatic NSCLC who have progressed on a targeted therapy

EGFR mutated advanced or metastatic NSCLC who have progressed on an EGFR
TKI

I

NCT03260491170

Patient Population

Phase

Protocol Name

Table 7 (Continued).
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conditions or those who have been treated with radiation in
the past. This usually consists of interstitial lung disease/
pneumonitis. While the exact mechanism is unclear, this is
thought to be due to inhibition of EGFR, which is expressed
in type II pneumocytes, which helps in alveolar wall repair.
Management is supportive, with immediate discontinuation
of the drug, oxygen supplementation, and steroids.69
Osimertinib has shown to have a higher incidence of pul
monary toxicity compared to first-generation EGFR TKIs.43

Cardiac Toxicity with EGFR TKI
Cardiac toxicity including QT prolongation, cardiac fail
ure, pericardial effusion, myocarditis, atrial fibrillation
although uncommon, has been seen with osimertinib.43
The exact mechanism is not known but is thought to be
due to the inhibition of HER 2 (human epidermal growth
factor-2).85 Treatment includes supportive measures, max
imizing cardiac protection and sometimes discontinuation
of the drug.

Evolving Treatment Paradigm for EGFR
Positive Metastatic NSCLC
Currently, for patients who have EGFR positive meta
static NSCLC, treatment options consist of erlotinib,
gefitinib, icotinib, afatinib, dacomitinib, osimertinib or
erlotinib plus ramucirumab.23–45,61 Osimertinib has
emerged as the preferred EGFR TKI due to its benefit
in PFS and OS over erlotinib and gefitinib.43,54 The
most common cause for secondary resistance to first
and second-generation TKI is development of
a secondary mutation in exon 20, T790M. Osimertinib
is an effective second-line option for patients who were
previously treated with first or second-generation TKI,
particularly for those who develop the T790M mutation.
Patients who progress on osimertinib have limited
options. Resistance mechanisms include occurrence of
tertiary mutations such as C797S, activation of alternate
signaling pathways such as MET, and histological trans
formation to small cell or sarcomatoid tumors.86 Options
after progression on osimertinib include continuing TKI
while addressing areas of progression with local thera
pies or initiating systemic platinum-based or docetaxel
chemotherapy.87 Checkpoint inhibitor therapy is gener
ally ineffective in this patient population.88,89
Enrollment in clinical trials is ideal and should be
strongly considered for these patients.

Lung Cancer: Targets and Therapy 2020:11

Lee et al

Conclusions and Future Directions
EGFR TKIs significantly improve outcomes in patients
with advanced NSCLC that contains an activating muta
tion in EGFR compared with platinum-based chemother
apy doublets. Resistance inevitably occurs and identifying
patients who are likely to have rapid progression is critical.
This would not only help with monitoring patients on
treatment but also help optimize outcomes by encouraging
them to participate in clinical trials.
There are emerging data to support the use of EGFR
TKIs with other systemic therapies in the front-line set
ting. While most of the published studies on combination
therapies have involved first-generation TKIs, there are
ongoing trials looking at combinations of various TKIs
including osimertinib with other systemic agents as sum
marized in Table 7. It is possible that these combinations
will push median survival even further for these patients,
but the incremental benefit needs to be weighed against
additional toxicities from adding other systemic agents.
Currently, osimertinib is the preferred therapy of choice
of EGFR-mutated NSCLC, but the promising data for
combination therapies raise the question as to which
option would be better suited as first-line therapy. PFS
was similar amongst the trials, but osimertinib may be
a suitable option after progression on combination
therapy.43,57–61
Developing effective treatment regimens for patients
who progress on osimertinib, or those who develop tertiary
mutations such as C797S, is urgently needed. Patients with
less common EGFR mutations such as exon 20 insertions
typically do not respond well to the available TKIs and there
is an imminent need to develop agents that work effectively
in this population (Table 7). Similarly, patients with refrac
tory brain metastases or leptomeningeal disease desperately
need efficient treatment options. Table 7 enlists some of the
ongoing clinical trials that aim to address these unmet needs.
With multiple agents approved for EGFR-mutated
NSCLC, it would be ideal to have standardization of clinical
pathways, including guidelines on optimal utilization of tis
sue-based and blood-based next-generation sequencing.
Multidisciplinary input, in addition to detailed genomic
information, is of paramount importance to help create
a personalized treatment plan for each patient. These thera
pies do come with unforeseen adverse effects, for which
having an interdisciplinary team including oncologists,
nurses, clinical pharmacists, dermatologists, gastroenterolo
gists, dentist/oral health-care providers, and wound care
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specialists, is of utmost importance. Patient education regard
ing toxicities prior to initiation of treatment, in conjunction
with the utilization of patient-reported outcomes, and toxicity
management algorithms, help improve patients’ quality of
life. These strategies increase patient compliance while also
reducing treatment interruptions, dose reductions, or treat
ment discontinuation.

Conclusion
EGFR mutated advanced NSCLC forms a special subset of
lung cancer for which there are excellent treatment
options. The current standard of care for patients diag
nosed with this disease is treated with one of the several
FDA-approved TKIs, which have all shown improved out
comes compared to chemotherapy. However, almost all
patients with this disease develop resistance at some time
point and there are no effective treatment options for
patients who progress on the third-generation TKI, osimer
tinib. Ongoing trials with combination regimens and poly
specific antibodies will hopefully address unmet needs and
transform EGFR-mutated lung cancer to a chronic disease
with an excellent prognosis.
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